Table 2.

Treatment characteristics and adverse events among patients with DR-TB treated with a LZD-containing regimen

Characteristic	N = 100
Time from DR-TB treatment initiation to starting LZD, days, median [IQR]	29 [0–179]
LZD starting dose of 600 mg/day	99
Dose reduction to 300 mg/day	7
Total duration of LZD treatment, days, median [IQR]*	503 [355–616]
Duration of LZD 600 mg treatment, days, median [IQR] (n = 99)	486 [338–612]
Time to LZD dose reduction, days, median [IQR] (n = 7)	219 [134–351]
Duration of LZD 300 mg treatment, days, median [IQR] (n = 8)	265 [161–364]
LZD-attributed adverse events
Any adverse event	12
PNP	8
LZD stopped due to PNP	2
LZD dose reduced due to PNP	4
LZD continued without dose reduction	2
Time to LZD discontinuation or dose reduction among patients with PNP, days, median [IQR]	162 [86–286]
Cytopenias	4
LZD stopped due to cytopenias	2
LZD dose reduced due to cytopenias	2
Time to LZD discontinuation or dose reduction among patients with cytopenias days median [IQR]	111 [90–248]

^*Duration of LZD treatment was as follows: in the cured (n = 79; median 598 days, IQR 399–627); in patients who stopped LZD due to adverse events (n = 4; median 138 days, IQR 60–315); in those lost to follow up/died (n = 21; median 274 days, IQR 197–392).

DR-TB = drug-resistant tuberculosis; LZD = linezolid; IQR = interquartile range; PNP = peripheral neuropathy.